Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:494-500
Published online before print December 15, 2005, doi: 10.1161/01.ATV.0000200135.61362.27
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/3/494    most recent
01.ATV.0000200135.61362.27v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, M. Y.
Right arrow Articles by Chait, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, M. Y.
Right arrow Articles by Chait, A.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:494.)
© 2006 American Heart Association, Inc.


Vascular Biology

Antioxidants Inhibit the Ability of Lysophosphatidylcholine to Regulate Proteoglycan Synthesis

Mary Y. Chang; Chang-Yeop Han; Thomas N. Wight; Alan Chait

From the Department of Medicine (M.Y.C., C.-Y.H., A.C.), University of Washington, and Hope Heart Institute (T.N.W.), Seattle, Wash.

Correspondence to Mary Y. Chang, Box 356426, University of Washington, Seattle, WA 98195-6426. E-mail mychang{at}u.washington.edu

Objective— We previously have shown that lysophosphatidylcholine (lysoPC) regulates proteoglycan synthesis by vascular smooth muscle cells (SMCs). Given the accumulating evidence for reactive oxygen species (ROS) as mediators of a variety of effects of lysoPC, the present study evaluates the potential role of ROS as intermediate molecules in the regulation of proteoglycan synthesis by lysoPC.

Methods and Results— LysoPC (10 µmol/L) was found to stimulate rapid and sustained generation of ROS by SMC, as indicated using a fluorescent probe for measuring intracellular oxidants and fluorescence-activated cell sorting. This was not associated with cytotoxicity, as evaluated by fluorescence microscopy using MitoTracker Red or propidium iodide, cell number, cell protein, or lactate dehydrogenase release. Pretreatment with catalase or superoxide dismutase, specific scavengers of hydrogen peroxide and superoxide, respectively, blocked the ability of lysoPC to stimulate both accumulation of ROS and proteoglycan synthesis. Most importantly, these enzymatic antioxidants prevented lysoPC from stimulating the synthesis of proteoglycans with enhanced lipoprotein-binding properties, as quantified by a gel shift binding assay.

Conclusions— These findings strongly suggest that ROS are key mediators in the ability of lysoPC to regulate proteoglycan synthesis and that these effects can be inhibited by antioxidants.

We previously have shown that lysoPC regulates proteoglycan synthesis by vascular smooth muscle cells. Current findings strongly suggest that reactive oxygen species are key mediators in this ability of lysoPC and that these effects can be inhibited by antioxidants.


Key Words: antioxidants • catalase • lysophosphatidylcholine • PG-MCSF • proteoglycans • reactive oxygen species • superoxide dismutase